<SEC-DOCUMENT>0001209191-21-042145.txt : 20210621
<SEC-HEADER>0001209191-21-042145.hdr.sgml : 20210621
<ACCEPTANCE-DATETIME>20210621171913
ACCESSION NUMBER:		0001209191-21-042145
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210618
FILED AS OF DATE:		20210621
DATE AS OF CHANGE:		20210621

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Zeronda Tyler
		CENTRAL INDEX KEY:			0001867033

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38356
		FILM NUMBER:		211031948

	MAIL ADDRESS:	
		STREET 1:		C/O VYNE THERAPEUTICS
		STREET 2:		520 U.S. HIGHWAY 22, SUITE 204
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VYNE Therapeutics Inc.
		CENTRAL INDEX KEY:			0001566044
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				453757789
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		520 U.S. HIGHWAY 22, SUITE 204
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		800-775-7936

	MAIL ADDRESS:	
		STREET 1:		520 U.S. HIGHWAY 22, SUITE 204
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Menlo Therapeutics Inc.
		DATE OF NAME CHANGE:	20180201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Menlo Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170728

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tigercat Pharma, Inc.
		DATE OF NAME CHANGE:	20130104
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>doc3.xml
<DESCRIPTION>FORM 3 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2021-06-18</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001566044</issuerCik>
        <issuerName>VYNE Therapeutics Inc.</issuerName>
        <issuerTradingSymbol>VYNE</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001867033</rptOwnerCik>
            <rptOwnerName>Zeronda Tyler</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O VYNE THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>520 U.S. HIGHWAY 22, SUITE 204</rptOwnerStreet2>
            <rptOwnerCity>BRIDGEWATER</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>08807</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Interim CFO</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>23395</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>5.92</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2029-05-16</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>13504</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>10.68</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2030-03-19</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>4375</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>7.80</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <value>2030-05-06</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>9375</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>6.68</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F5"/>
            </exerciseDate>
            <expirationDate>
                <value>2031-03-04</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>18834</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">This amount includes 18,853 shares underlying unvested restricted stock units that will vest over four years following the date of grant.</footnote>
        <footnote id="F2">The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option vested on June 30, 2020 and 6.25% of the shares vest on the last day of each quarter thereafter.</footnote>
        <footnote id="F3">The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option vested on March 31, 2021 and 6.25% of the shares will vest on the last day of each quarter thereafter.</footnote>
        <footnote id="F4">The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on June 30, 2021 and 6.25% of the shares will vest on the last day of each quarter thereafter.</footnote>
        <footnote id="F5">The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2022 and 6.25% of the shares will vest on the last day of each quarter thereafter.</footnote>
    </footnotes>

    <remarks>The reporting person was not granted any additional awards in connection with his appointment as interim CFO of the Issuer.</remarks>

    <ownerSignature>
        <signatureName>/s/ Mutya Harsch, attorney-in-fact for Tyler Zeronda</signatureName>
        <signatureDate>2021-06-21</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>attachment1.htm
<DESCRIPTION>EX-24 DOCUMENT
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Skadden Arps
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;
text-align: left; color: #000000;" bgcolor="#ffffff">
  <div><br>
  </div>
  <div>
    <div style="text-align: center; font-family: 'Times New Roman', serif;
font-size: 12pt; font-weight: bold;">POWER OF ATTORNEY</div>
    <div style="text-align: center; margin-bottom: 8pt; font-family: 'Times New
Roman', serif; font-size: 12pt; font-weight: bold;">For Executing Forms 3, 4 and
5</div>
    <div style="margin-bottom: 8pt; font-family: 'Times New Roman', serif;
font-size: 12pt;">KNOW ALL BY THESE PRESENTS, that the undersigned hereby
constitutes and appoints Mutya Harsch, Chief Legal Officer and General Counsel,
and David
      Weinfeld, Assistant General Counsel of VYNE Therapeutics Inc.
(&#8220;VYNE&#8221;), or any of them, each acting alone, his or her true and
lawful attorney-in-fact to:</div>
    <div style="margin-bottom: 8pt;"><font style="font-family: 'Times New
Roman', serif; font-size:
12pt;">(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font
style="font-family: 'Times New Roman', serif; font-size: 12pt;">execute for and
on behalf of the
        undersigned a Form 3, Form 4 or Form 5, or any amendment thereto,
relating to the securities of VYNE, in accordance with Section 16(a) of the
Securities Exchange Act of 1934 and the rules thereunder;</font></div>
    <div style="margin-bottom: 8pt;"><font style="font-family: 'Times New
Roman', serif; font-size:
12pt;">(2)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font
style="font-family: 'Times New Roman', serif; font-size: 12pt;">do and perform
any and all acts for and
        on behalf of the undersigned which may be necessary or desirable to
complete the execution of such Form 3, Form 4 or Form 5, or any amendment
thereto, and the timely filing of such form with the United States Securities
and Exchange Commission and
        any other authority; and</font></div>
    <div style="margin-bottom: 8pt;"><font style="font-family: 'Times New
Roman', serif; font-size:
12pt;">(3)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font
style="font-family: 'Times New Roman', serif; font-size: 12pt;">take any other
action of any type
        whatsoever in connection with the foregoing which, in the opinion of
such attorney-in-fact, may be of benefit to, in the best interest of, or legally
required by, the undersigned, it being understood that the documents executed by
such
        attorney-in-fact on behalf of the undersigned pursuant to this Power of
Attorney shall be in such form and shall contain such terms and conditions as
such attorney-in-fact may approve in his discretion.</font></div>
    <div style="margin-bottom: 8pt; font-family: 'Times New Roman', serif;
font-size: 12pt;">The undersigned hereby grants to such attorney-in-fact full
power and authority to do and perform all and every act and thing whatsoever
      requisite, necessary and proper to be done in the exercise of any of the
rights and powers herein granted, as fully to all intents and purposes as such
attorney-in-fact might or could do if personally present, hereby ratifying and
confirming that
      such attorney-in-fact shall lawfully do or cause to be done by virtue of
this Power of Attorney and the rights and powers herein granted.&#160; The
undersigned acknowledges that the foregoing attorney-in-fact, in serving in such
capacity at the request of
      the undersigned, is not assuming any of the undersigned&#8217;s
responsibilities to comply with Section 16 of the Securities Exchange Act of
1934.&#160; This Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to
      file Forms 3, 4 and 5 with respect to the undersigned&#8217;s holdings of
and transactions in securities issued by VYNE unless earlier revoked by the
undersigned in a signed writing delivered to the foregoing
attorneys-in-fact.</div>
    <div style="margin-bottom: 8pt; font-family: 'Times New Roman', serif;
font-size: 12pt;">IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of this 18<sup style="vertical-align: text-top;
line-height: 1; font-size: smaller;">th</sup> day of June, 2021.</div>
    <div style="margin-bottom: 8pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;
width: 100%; border-collapse: collapse; text-align: left; color: #000000;"
id="z4a18c971ce2e4252be957ba1bdc52057" border="0" cellpadding="0"
cellspacing="0">

        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif; font-size:
12pt;">By:</div>
          </td>
          <td style="width: 30%; vertical-align: top; border-bottom: 0.5pt solid
rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', serif; font-size:
12pt;">/s/ Tyler Zeronda</div>
          </td>
          <td style="width: 20%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top; white-space: nowrap; width: 5%;">
            <div style="font-family: 'Times New Roman', serif; font-size:
12pt;">Name:&#160;&#160;&#160; <br>
            </div>
          </td>
          <td style="width: 30%; vertical-align: top; border-top: 0.5pt solid
rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', serif; font-size:
12pt;">Tyler Zeronda</div>
          </td>
          <td style="width: 20%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div style="margin-bottom: 8pt;"><br>
    </div>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
